24 results on '"Padhye B."'
Search Results
2. 286P Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
- Author
-
Body, A., primary, Ahern, E.S., additional, Lal, L., additional, Abdulla, H., additional, Opat, S., additional, Downie, P., additional, Leahy, M., additional, Fuentes-Bolanos, N., additional, Padhye, B., additional, Hamad, N., additional, Milch, V., additional, and Segelov, E., additional
- Published
- 2022
- Full Text
- View/download PDF
3. SHEDDING LIGHT ON GREY ZONE LYMPHOMA
- Author
-
Mason, N., primary, Padhye, B., additional, and Bateman, C., additional
- Published
- 2022
- Full Text
- View/download PDF
4. COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children's Haematology/Oncology Group consensus statement.
- Author
-
Furlong E., Kotecha R.S., Conyers R., O'Brien T.A., Hansford J.R., Super L., Downie P., Eisenstat D.D., Haeusler G., McMullan B., Phillips M.B., Padhye B., Dalla-Pozza L., Alvaro F., Fraser C.J., Nicholls W., Clark J.E., O'Connor M., Saxon B.R., Tapp H., Heath J., Hunter S.E., Tsui K., Winstanley M., Lyver A., Best E.J., Wadia U., Yeoh D., Blyth C.C., Gottardo N.G., Furlong E., Kotecha R.S., Conyers R., O'Brien T.A., Hansford J.R., Super L., Downie P., Eisenstat D.D., Haeusler G., McMullan B., Phillips M.B., Padhye B., Dalla-Pozza L., Alvaro F., Fraser C.J., Nicholls W., Clark J.E., O'Connor M., Saxon B.R., Tapp H., Heath J., Hunter S.E., Tsui K., Winstanley M., Lyver A., Best E.J., Wadia U., Yeoh D., Blyth C.C., and Gottardo N.G.
- Abstract
Introduction: The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged >= 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19. There remains a paucity of data regarding the immune response to COVID-19 vaccines in immunosuppressed paediatric populations, with data suggestive of reduced immunogenicity of the vaccine in immunocompromised adults. Recommendations: Considering the safety profile of mRNA COVID-19 vaccines and the increased risk of severe COVID-19 in immunocompromised children and adolescents, COVID-19 vaccination is strongly recommended for this at-risk population. We provide a number of recommendations regarding COVID-19 vaccination in this population where immunosuppressive, chemotherapeutic and/or targeted biological agents are used. These include the timing of vaccination in patients undergoing active treatment, management of specific situations where vaccination is contraindicated or recommended under special precautions, and additional vaccination recommendations for severely immunocompromised patients. Finally, we stress the importance of upcoming clinical trials to identify the safest and most efficacious vaccination regimen for this population. Changes in management as a result of this statement: This consensus statement provides recommendations for COVID-19 vaccination in children and adolescents aged >= 5 years with cancer and immunocompromising non-malignant haematological conditions, based on evidence, national and international guidelines and expert opinion. Endorsed by
- Published
- 2022
5. Diagnostic Yield of Initial and Consecutive Blood Cultures in Children with Cancer and Febrile Neutropenia.
- Author
-
Haeusler G.M., De Abreu Lourenco R., Clark H., Thursky K.A., Slavin M.A., Babl F.E., Mechinaud F., Alvaro F., Clark J., Padhye B., Phillips M., Super L., Tapp H., Walwyn T., Ziegler D., Phillips R., Worth L.J., Haeusler G.M., De Abreu Lourenco R., Clark H., Thursky K.A., Slavin M.A., Babl F.E., Mechinaud F., Alvaro F., Clark J., Padhye B., Phillips M., Super L., Tapp H., Walwyn T., Ziegler D., Phillips R., and Worth L.J.
- Abstract
Background: The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics. Method(s): Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken. Result(s): A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P <. 001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures. Conclusion(s): In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals.Copyright © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
- Published
- 2021
6. Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents
- Author
-
Crothers, A, Haeusler, GM, Slavin, MA, Babl, FE, Mechinaud, F, Phillips, R, Tapp, H, Padhye, B, Zeigler, D, Clark, J, Walwyn, T, Super, L, Alvaro, F, Thursky, K, Lourenco, RDA, Crothers, A, Haeusler, GM, Slavin, MA, Babl, FE, Mechinaud, F, Phillips, R, Tapp, H, Padhye, B, Zeigler, D, Clark, J, Walwyn, T, Super, L, Alvaro, F, Thursky, K, and Lourenco, RDA
- Abstract
BACKGROUND: The impact febrile neutropenia (FN) has on the health-related quality of life (HRQoL) of children with cancer and their families is poorly understood. We sought to characterize the course of child and parent HRQoL during and following FN episodes. METHOD: Data on HRQoL were collected in the multisite Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study. Participants were enrolled between November 2016 to January 2018. The Child Health Utility (CHU9D) was used to assess HRQoL in children (N = 167 FN events) and the Assessment of Quality of Life (AQoL-8D) was used to assess HRQoL parents (N = 218 FN events) at three time points: 0-3 days, 7-days and 30-days following the onset of FN. Group-based trajectory modeling (GBTM) was used to characterize the course of HRQoL. FINDINGS: For children, three distinct groups were identified: persistently low HRQoL over the 30-day course of follow-up (chronic: N = 78/167; 47%), increasing HRQoL after the onset of FN to 30 days follow-up (recovering: N = 36/167; 22%), and persistently high HRQoL at all three timepoints (resilient: N = 53/167; 32%). Applying these definitions, parents were classified into two distinct groups: chronic (N = 107/218, 49%) and resilient (N = 111/218, 51%). The child being male, having solid cancer, the presence of financial stress, and relationship difficulties between the parent and child were significant predictors of chronic group membership for both parents and children. Children classified as high-risk FN were significantly more likely to belong to the recovery group. Being female, having blood cancers and the absence of financial or relationship difficulties were predictive of both parents and children being in the resilient group. INTERPRETATION: Approximately half the children and parents had chronically low HRQoL scores, which did not improve following resolution of the FN episode. The child's sex, cancer type, and presence of financial and relations
- Published
- 2021
7. Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia
- Author
-
Haeusler, GM, De Abreu Lourenco, R, Clark, H, Thursky, KA, Slavin, MA, Babl, FE, Mechinaud, F, Alvaro, F, Clark, J, Padhye, B, Phillips, M, Super, L, Tapp, H, Walwyn, T, Ziegler, D, Phillips, R, Worth, LJ, Haeusler, GM, De Abreu Lourenco, R, Clark, H, Thursky, KA, Slavin, MA, Babl, FE, Mechinaud, F, Alvaro, F, Clark, J, Padhye, B, Phillips, M, Super, L, Tapp, H, Walwyn, T, Ziegler, D, Phillips, R, and Worth, LJ
- Abstract
BACKGROUND:The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics. METHODS:Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken. RESULTS:A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P < .001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures. CONCLUSIONS:In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals.
- Published
- 2021
8. 2106P Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
- Author
-
Body, A., Donoghoe, M.W., Ahern, E.S., Lal, L., Downie, P., Leahy, M.F., Fuentes-Bolanos, N., Anazodo, A., Padhye, B., Hamad, N., Wakefield, C.E., and Segelov, E.
- Published
- 2023
- Full Text
- View/download PDF
9. Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia.
- Author
-
Worth L.J., Ziegler D., Phillips R., Super L., Haeusler G.M., De Abreu Lourenco R., Clark H., Thursky K.A., Slavin M.A., Babl F.E., Mechinaud F., Alvaro F., Clark J., Padhye B., Phillips M., Tapp H., Walwyn T., Worth L.J., Ziegler D., Phillips R., Super L., Haeusler G.M., De Abreu Lourenco R., Clark H., Thursky K.A., Slavin M.A., Babl F.E., Mechinaud F., Alvaro F., Clark J., Padhye B., Phillips M., Tapp H., and Walwyn T.
- Abstract
BACKGROUND: The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics. METHOD(S): Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken. RESULT(S): A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P < .001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures. CONCLUSION(S): In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals.Copyright © The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
- Published
- 2020
10. 093 - SHEDDING LIGHT ON GREY ZONE LYMPHOMA
- Author
-
Mason, N., Padhye, B., and Bateman, C.
- Published
- 2022
- Full Text
- View/download PDF
11. QUALITY OF LIFE-AFTER COMPLITION OF THERAPY-EXPERIENCE IN AFTER COMPLETION OF THERAPY CLINIC IN INDIA: P.U.013
- Author
-
Goswami, S., Kurkure, P, Dalvi, N, Pradhan, P, and Padhye, B
- Published
- 2005
12. Results of chemotherapy (CT) based protocol for treatment of retinoblastoma (RB)
- Author
-
Goyal, L., primary, Banavali, S., additional, Bhagwat, R., additional, Arora, B., additional, Muckaden, M., additional, Laskar, S., additional, Padhye, B., additional, Nicholson, A., additional, Kurkure, P., additional, and Parikh, P., additional
- Published
- 2006
- Full Text
- View/download PDF
13. Low-Level BCR::ABL1 Transcript at Diagnosis in Childhood Leukemia: A 10-Year Single Institution Study.
- Author
-
Cain LE, Mirochnik O, Stevens MM, Kellie SJ, Padhye B, Keogh SJ, Govender D, Ryan J, Dalla-Pozza L, and Bateman CM
- Subjects
- Humans, Child, Male, Female, Child, Preschool, Adolescent, Retrospective Studies, In Situ Hybridization, Fluorescence, Infant, Philadelphia Chromosome, Fusion Proteins, bcr-abl genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Introduction: Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is a high risk form of ALL associated with dismal outcomes in the pre-tyrosine kinase inhibitor (TKI) era. Addition of a TKI to chemotherapy improves outcomes. Therefore, testing for the presence of the Philadelphia chromosome by at least two methods at the time of diagnosis is critical. Diagnostic testing may include karyotype, fluorescent in situ hybridisation (FISH), and RT-PCR for the BCR::ABL1 transcript. The significance of low-level BCR::ABL1 transcript by RT-PCR in the absence of the Philadelphia chromosome on karyotype or by FISH is unknown., Methods: This is a retrospective review of children diagnosed with acute leukemia at our institution from 2010 to 2020. Those positive for the BCR::ABL1 transcript by qualitative RT-PCR, and negative for t(9;22) by karyotype or FISH were analyzed for demographics, cytogenetic and molecular features at diagnosis and relapse, treatment and outcomes. The Kaplan-Meier method was used to estimate event-free and overall survival., Results: Forty-seven of 306 (15%) patients with Ph- ALL had low-level BCR::ABL1 detected by RT-PCR. Most (77%) had B-cell ALL. The e1a2 transcript was detected most frequently, in 43 (91%) patients. BCR::ABL1 was quantifiable in 12/43 (28%) patients, with a median of 0.0008% (range 0.0003-0.095%). Seven patients (15%) relapsed. No patient with low-level BCR::ABL1 at diagnosis developed Ph + ALL at relapse. There was no difference in 5-year event-free (77% versus 81%, p = 0.407) or overall survival (86% versus 91%, p = 0.3) between children with low-level BCR::ABL1 (n = 47) and those without (n = 259)., Conclusion: BCR::ABL1 low-level positivity in children with newly diagnosed Ph- ALL is a relatively common finding and did not adversely affect outcome for patients treated using a contemporary risk-adapted approach., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
14. Protocol for a comprehensive prospective cohort study of trio-based whole-genome sequencing for underlying cancer predisposition in paediatric and adolescent patients newly diagnosed with cancer: the PREDICT study.
- Author
-
Fuentes Bolanos NA, Padhye B, Daley M, Hunter J, Hetherington K, Warby M, Courtney E, Kirk J, Josephi-Taylor S, Chen Y, Alvaro F, Barlow-Stewart K, Wong-Erasmus M, Barahona P, Ajuyah P, Altekoester AK, Tyrrell VJ, Lau LMS, Wakefield C, Sylvester D, Tucker K, Pinese M, Dalla Pozza L, and O'Brien TA
- Subjects
- Adolescent, Child, Humans, Cohort Studies, Disease Susceptibility, Genetic Predisposition to Disease, Prospective Studies, Whole Genome Sequencing methods, Neoplasms diagnosis, Neoplasms genetics
- Abstract
Introduction: Identifying an underlying germline cancer predisposition (CP) in a child with cancer has potentially significant implications for both the child and biological relatives. Cohort studies indicate that 10%-15% of paediatric cancer patients carry germline pathogenic or likely pathogenic variants in cancer predisposition genes, but many of these patients do not meet current clinical criteria for genetic testing. This suggests broad tumour agnostic germline testing may benefit paediatric cancer patients. However, the utility and psychosocial impact of this approach remain unknown. We hypothesise that an approach involving trio whole-genome germline sequencing (trio WGS) will identify children and families with an underlying CP in a timely fashion, that the trio design will streamline cancer risk counselling to at-risk relatives if CP was inherited, and that trio testing will not have a negative psychosocial impact on families., Method and Analysis: To test this, we present the Cancer PREDisposition In Childhood by Trio sequencing study (PREDICT). This study will assess the clinical utility of trio WGS to identify CP in unselected patients with cancer 21 years or younger in New South Wales, Australia. PREDICT will perform analysis of biological parents to determine heritability and will examine the psychosocial impact of this trio sequencing approach. PREDICT also includes a broad genomics research programme to identify new candidate genes associated with childhood cancer risk., Ethics and Dissemination: By evaluating the feasibility, utility and psychosocial impact of trio WGS to identify CP in paediatric cancer, PREDICT will inform how such comprehensive testing can be incorporated into a standard of care at diagnosis for all childhood cancer patients., Trial Registration Number: NCT04903782., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
15. Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.
- Author
-
Vanderniet JA, Tsinas D, Wall CL, Girgis CM, London K, Keane C, Briody J, Hibbert S, Poon M, Padhye B, Biggin A, Dalla-Pozza L, Gray RJ, and Munns CF
- Subjects
- Humans, Child, Denosumab therapeutic use, Australia, Spine pathology, Bone Cysts, Aneurysmal drug therapy, Bone Cysts, Aneurysmal surgery, Hypercalcemia drug therapy, Bone Density Conservation Agents therapeutic use
- Abstract
Aneurysmal bone cysts (ABC) are rare osteolytic, benign but often locally aggressive tumours of the long bones or vertebrae. For spinal ABC, surgical management, embolisation or sclerotherapy alone often carry high morbidity and/or high recurrence rates. Interruption of receptor activator of nuclear factor-kappa B ligand (RANKL) signalling holds promise as an effective therapeutic strategy for these tumours. We aimed to review the approach to surgical management and evaluate the efficacy and safety of denosumab for ABC of the spine in children. Retrospective review of 7 patients treated with denosumab using a standardised protocol for ABC of the spine in a tertiary paediatric centre. Surgical intervention was only conducted if there was spinal instability or significant neurological impairment. Denosumab 70 mg/m
2 was given 4-weekly for at least 6 months, followed by 2 doses of zoledronate 0.025 mg/kg, aiming to prevent rebound hypercalcaemia. All patients achieved stability of the spine and resolution of neurological impairment, if present. Six patients achieved metabolic remission and have ceased denosumab without recurrence to date; the other showed clinical and radiological improvement without complete metabolic remission. Three patients developed symptomatic hypercalcaemia 5-7 months after cessation of denosumab, requiring additional bisphosphonate treatment. We present our algorithm for the surgical and medical management of paediatric spinal ABC. Denosumab produced a radiological and metabolic response in all patients, with complete remission in most. Follow-up time was not long enough to evaluate the endurance of response after cessation in some patients. Incidence of rebound hypercalcaemia in this paediatric cohort was high, prompting a change to our protocol., (© 2023. Crown.)- Published
- 2023
- Full Text
- View/download PDF
16. Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre.
- Author
-
Vanderniet JA, Wall CL, Mullins A, London K, Lim L, Hibbert S, Briody J, Padhye B, Poon M, Biggin A, Dalla-Pozza L, and Munns CF
- Subjects
- Australia, Child, Denosumab therapeutic use, Humans, Bone Density Conservation Agents adverse effects, Bone Neoplasms drug therapy, Giant Cell Tumor of Bone pathology, Granuloma, Giant Cell chemically induced, Granuloma, Giant Cell diagnostic imaging, Granuloma, Giant Cell drug therapy, Hypercalcemia drug therapy
- Abstract
Background: Central giant cell granulomas (CGCG) are rare osteolytic, benign but often locally aggressive tumours of bone. Surgical curettage may not be possible in extensive lesions and resection carries high morbidity, especially in growing children, and previous medical therapies have had variable efficacy and high recurrence rates. Interruption of receptor activator of nuclear factor-kappa B ligand (RANKL) signalling holds promise as an effective therapeutic strategy for these tumours., Aims: To evaluate the efficacy and safety of our protocol for denosumab treatment of CGCG in children., Methods: Retrospective review of 4 patients treated with denosumab using a standardised protocol for CGCG in a tertiary paediatric centre. Denosumab 70 mg/m
2 was given 4-weekly, followed by 2 doses of zoledronate 0.025 mg/kg, aimed at preventing rebound hypercalcaemia., Results: Treatment of CGCG resulted in metabolic remission in all patients, but recurrence, detected by positron emission tomography (PET), occurred at 6 months in three patients and 12 months in one patient. Three patients developed symptomatic hypercalcaemia 4-5 months and one patient asymptomatic hypercalcaemia 7 months after cessation of denosumab, with 3 requiring additional bisphosphonate treatment., Conclusions: Denosumab produced a radiological and metabolic response in our patients, but metabolic recurrence occurred in all patients. PET imaging was effective for monitoring treatment response and early detection of recurrence. Incidence of rebound hypercalcaemia in this paediatric cohort was high. We present proposed changes to our protocol with the aim of producing sustained remission and preventing rebound hypercalcaemia., (Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
17. COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children's Haematology/Oncology Group consensus statement.
- Author
-
Furlong E, Kotecha RS, Conyers R, O'Brien TA, Hansford JR, Super L, Downie P, Eisenstat DD, Haeusler G, McMullan B, Phillips MB, Padhye B, Dalla-Pozza L, Alvaro F, Fraser CJ, Nicholls W, Clark JE, O'Connor M, Saxon BR, Tapp H, Heath J, Hunter SE, Tsui K, Winstanley M, Lyver A, Best EJ, Wadia U, Yeoh D, Blyth CC, and Gottardo NG
- Subjects
- Adolescent, Australia epidemiology, COVID-19 Vaccines, Child, Child, Preschool, Humans, New Zealand epidemiology, Vaccination, COVID-19 prevention & control, Hematology, Neoplasms therapy
- Abstract
Introduction: The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19. There remains a paucity of data regarding the immune response to COVID-19 vaccines in immunosuppressed paediatric populations, with data suggestive of reduced immunogenicity of the vaccine in immunocompromised adults., Recommendations: Considering the safety profile of mRNA COVID-19 vaccines and the increased risk of severe COVID-19 in immunocompromised children and adolescents, COVID-19 vaccination is strongly recommended for this at-risk population. We provide a number of recommendations regarding COVID-19 vaccination in this population where immunosuppressive, chemotherapeutic and/or targeted biological agents are used. These include the timing of vaccination in patients undergoing active treatment, management of specific situations where vaccination is contraindicated or recommended under special precautions, and additional vaccination recommendations for severely immunocompromised patients. Finally, we stress the importance of upcoming clinical trials to identify the safest and most efficacious vaccination regimen for this population., Changes in Management as a Result of This Statement: This consensus statement provides recommendations for COVID-19 vaccination in children and adolescents aged ≥ 5 years with cancer and immunocompromising non-malignant haematological conditions, based on evidence, national and international guidelines and expert opinion., Endorsed by: The Australian and New Zealand Children's Haematology/Oncology Group., (© 2022 AMPCo Pty Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
18. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer.
- Author
-
Sylvester DE, Chen Y, Grima N, Saletta F, Padhye B, Bennetts B, Wright D, Krivanek M, Graf N, Zhou L, Catchpoole D, Kirk J, Latchoumanin O, Qiao L, Ballinger M, Thomas D, Jamieson R, Dalla-Pozza L, and Byrne JA
- Subjects
- Adolescent, Aged, Child, Child, Preschool, Cohort Studies, Humans, Infant, Infant, Newborn, Exome Sequencing, Genetic Predisposition to Disease epidemiology, Genetic Predisposition to Disease genetics, Germ-Line Mutation genetics, Neoplasms epidemiology, Neoplasms genetics
- Abstract
Identification of cancer-predisposing germline variants in childhood cancer patients is important for therapeutic decisions, disease surveillance and risk assessment for patients, and potentially, also for family members. We investigated the spectrum and prevalence of pathogenic germline variants in selected childhood cancer patients with features suggestive of genetic predisposition to cancer. Germline DNA was subjected to exome sequencing to filter variants in 1048 genes of interest including 176 known cancer predisposition genes (CPGs). An enrichment burden analysis compared rare deleterious germline CPG variants in the patient cohort with those in a healthy aged control population. A subset of predicted deleterious variants in novel candidate CPGs was investigated further by examining matched tumor samples, and the functional impact of AXIN1 variants was analyzed in cultured cells. Twenty-two pathogenic/likely pathogenic (P/LP) germline variants detected in 13 CPGs were identified in 19 of 76 patients (25.0%). Unclear association with the diagnosed cancer types was observed in 11 of 19 patients carrying P/LP CPG variants. The burden of rare deleterious germline variants in autosomal dominant CPGs was significantly higher in study patients versus healthy aged controls. A novel AXIN1 frameshift variant (Ser321fs) may impact the regulation of β-catenin levels. Selection of childhood cancer patients for germline testing based on features suggestive of an underlying genetic predisposition could help to identify carriers of clinically relevant germline CPG variants, and streamline the integration of germline genomic testing in the pediatric oncology clinic., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
19. Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents.
- Author
-
Crothers A, Haeusler GM, Slavin MA, Babl FE, Mechinaud F, Phillips R, Tapp H, Padhye B, Zeigler D, Clark J, Walwyn T, Super L, Alvaro F, Thursky K, and De Abreu Lourenco R
- Abstract
Background: The impact febrile neutropenia (FN) has on the health-related quality of life (HRQoL) of children with cancer and their families is poorly understood. We sought to characterize the course of child and parent HRQoL during and following FN episodes., Method: Data on HRQoL were collected in the multisite Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study. Participants were enrolled between November 2016 to January 2018. The Child Health Utility (CHU9D) was used to assess HRQoL in children ( N = 167 FN events) and the Assessment of Quality of Life (AQoL-8D) was used to assess HRQoL parents ( N = 218 FN events) at three time points: 0-3 days, 7-days and 30-days following the onset of FN. Group-based trajectory modeling (GBTM) was used to characterize the course of HRQoL., Findings: For children, three distinct groups were identified: persistently low HRQoL over the 30-day course of follow-up (chronic: N = 78/167; 47%), increasing HRQoL after the onset of FN to 30 days follow-up (recovering: N = 36/167; 22%), and persistently high HRQoL at all three timepoints (resilient: N = 53/167; 32%). Applying these definitions, parents were classified into two distinct groups: chronic ( N = 107/218, 49%) and resilient ( N = 111/218, 51%). The child being male, having solid cancer, the presence of financial stress, and relationship difficulties between the parent and child were significant predictors of chronic group membership for both parents and children. Children classified as high-risk FN were significantly more likely to belong to the recovery group. Being female, having blood cancers and the absence of financial or relationship difficulties were predictive of both parents and children being in the resilient group., Interpretation: Approximately half the children and parents had chronically low HRQoL scores, which did not improve following resolution of the FN episode. The child's sex, cancer type, and presence of financial and relationship stress were predictive of chronic group membership for both parents and children. These families may benefit from increased financial and psychosocial support during anti-cancer treatment., Funding: National Health and Medical Research Council Grant (APP1104527)., Competing Interests: DZ reports personal fees from Bayer, personal fees from Amgen and personal fees from Day One, outside the submitted work. AC reports grants from NHMRC APP1104527, during the conduct of the study. GMH reports grants from NHMRC APP1104527 and the Victorian Cancer Agency early career fellowship, during the conduct of the study. MAS reports grants from Merck, from Gilead Sciences, and from F2G, personal fees from Pfizer and personal fees from Gilead Sciences, outside the submitted work. RDAL reports grants from NHMRC APP1104527, during the conduct of the study. RP reports grants from NIHR, during the conduct of the study. All the other authors report no conflicts., (Crown Copyright © 2021 Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
20. Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia.
- Author
-
Haeusler GM, De Abreu Lourenco R, Clark H, Thursky KA, Slavin MA, Babl FE, Mechinaud F, Alvaro F, Clark J, Padhye B, Phillips M, Super L, Tapp H, Walwyn T, Ziegler D, Phillips R, and Worth LJ
- Subjects
- Anti-Bacterial Agents therapeutic use, Australia, Blood Culture, Child, Humans, Febrile Neutropenia diagnosis, Febrile Neutropenia drug therapy, Fever of Unknown Origin drug therapy, Neoplasms complications, Neoplasms drug therapy
- Abstract
Background: The timing and necessity of repeated blood cultures (BCs) in children with cancer and febrile neutropenia (FN) are unknown. We evaluated the diagnostic yield of BCs collected pre- and post-empiric FN antibiotics., Methods: Data collected prospectively from the Australian Predicting Infectious ComplicatioNs in Children with Cancer (PICNICC) study were used. Diagnostic yield was calculated as the number of FN episodes with a true bloodstream infection (BSI) detected divided by the number of FN episodes that had a BC taken., Results: A BSI was identified in 13% of 858 FN episodes. The diagnostic yield of pre-antibiotic BCs was higher than of post-antibiotic cultures (12.3% vs 4.4%, P < .001). Two-thirds of the post-antibiotic BSIs were associated with a new episode of fever or clinical instability, and only 2 new BSIs were identified after 48 hours of empiric antibiotics and persistent fever. A contaminated BC was identified more frequently in post-antibiotic cultures., Conclusions: In the absence of new fever or clinical instability, BCs beyond 48 hours of persistent fever have limited yield. Opportunity exists to optimize BC collection in this population and reduce the burden of unnecessary tests on patients, healthcare workers, and hospitals., (© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
21. Clinical case series of pediatric hepatic angiosarcoma.
- Author
-
Grassia KL, Peterman CM, Iacobas I, Margolin JF, Bien E, Padhye B, Meyers RL, and Adams DM
- Subjects
- Child, Preschool, Female, Hemangiosarcoma therapy, Humans, Liver Neoplasms therapy, Liver Transplantation, Male, Prognosis, Hemangiosarcoma pathology, Liver Neoplasms pathology
- Abstract
Hepatic angiosarcoma is a rare, aggressive, malignant neoplasm with fewer than 50 cases reported in children. Prognosis is poor, with a minority surviving beyond 2 years after diagnosis. We report eight cases of pediatric hepatic angiosarcoma, diagnosed at a mean age of 3 years. Seven were initially diagnosed with an infantile hepatic hemangioendothelioma (IHHE) or hemangioma and the eighth with a "vascular tumor." Two patients, who received liver transplant, survived. We suggest hepatic hemangiomas can rarely transform into angiosarcomas and a subset of IHHEs (Type II) are actually a low-grade form of angiosarcoma rather than a benign lesion., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
22. Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).
- Author
-
Padhye B, Dalla-Pozza L, Little D, and Munns C
- Subjects
- Adolescent, Age Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Density Conservation Agents therapeutic use, Child, Child, Preschool, Diphosphonates therapeutic use, Female, Follow-Up Studies, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Humans, Imidazoles therapeutic use, Incidence, Magnetic Resonance Imaging, Male, Neoplasm, Residual, Osteonecrosis diagnostic imaging, Osteonecrosis drug therapy, Retrospective Studies, Risk Factors, Stem Cell Transplantation, Zoledronic Acid, Antineoplastic Combined Chemotherapy Protocols adverse effects, Osteonecrosis chemically induced, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Osteonecrosis (ON), a significant complication following treatment of acute lymphoblastic leukemia (ALL), has a profound impact on quality of life of ALL survivors. We studied incidence and outcome of ON in patients treated on or according to Australian and New Zealand Children's Haematology/ Oncology Group (ANZCHOG) study 8 at The Children's Hospital at Westmead. The study involved retrospective chart review of the patients. ON was defined by development of symptoms and confirmed by magnetic resonance imaging. From 2002-2011, 251 patients (143M, 108F, 59 Standard Risk (SR), 159 Medium Risk (MR) 5 High Risk (HR), and 28 Very high risk (VHR)) were treated according to study 8. Eighteen (7M, 11F, 2 SR, 12 MR, 4 VHR) patients developed ON (7.2%). Median age at diagnosis was 13.05 years(4.3-16.7). Incidence of ON in patients > 10 years at diagnosis was 29%. Six out of 18 patients developed ON after allogeneic stem cell transplantation. Median time from diagnosis to the development of ON following chemotherapy for ALL was 1.15 years (range 0.25-2.12). Most patients were treated with intravenous Zoledronic acid. At last follow-up, three patients had undergone arthroplasty, two patients were symptom free, and the remaining 13 patients reported persistent pain with activity. A majority of patients with ON of the hips had radiological progression. Overall, 7% of patients with ALL developed ON. Age >10 years was the most important risk factor. At last follow-up, 70% of patients had persistent symptoms. Although Zoledronic acid improved pain, most patients with ON of the hips had radiological progression., (© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
23. Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis.
- Author
-
Padhye B, Dalla-Pozza L, Little DG, and Munns CF
- Subjects
- Adolescent, Arthralgia chemically induced, Arthralgia diagnostic imaging, Arthralgia physiopathology, Arthralgia therapy, Arthroplasty, Bone Density drug effects, Bone Density Conservation Agents adverse effects, Child, Diphosphonates adverse effects, Female, Humans, Imidazoles adverse effects, Lymphoma diagnostic imaging, Lymphoma physiopathology, Male, Osteonecrosis diagnostic imaging, Osteonecrosis physiopathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnostic imaging, Precursor Cell Lymphoblastic Leukemia-Lymphoma physiopathology, Radiography, Retrospective Studies, Time Factors, Zoledronic Acid, Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Imidazoles administration & dosage, Lymphoma drug therapy, Osteonecrosis chemically induced, Osteonecrosis drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
Background: Osteonecrosis (ON) is a disabling complication of chemotherapy, especially steroids in children and adolescents. There are few reports in the literature of non-surgical management of ON. Patients with chemotherapy related ON, treated with zoledronic acid (ZA) were analyzed for clinical and radiological outcome., Methods: Retrospective chart review. Serial joint radiographs were performed to assess response and graded according to Association Research Circulation Osseous (ARCO) system. All patients were evaluated for bone turnover and bone mineral density (BMD) at set intervals., Results: Twenty children with ON were treated with ZA for median duration of 13 months (range 5-25) with median number of doses being 6 (2, 8). Five (25%) patients were pain free at the end of treatment and had minimal joint destruction on X-ray (ARCO score II); 5 (25%) underwent arthroplasty due to severe joint destruction and pain limiting activity (ARCO score III/IV); 10 (50%) reported ongoing pain with activity, none on regular analgesia. BMD analysis showed increase in lumbosacral BMD after 1 year of treatment. Compared to patients with ON of the knees, majority of patients with ON of the hips had radiological progression., Conclusion: ZA was well tolerated and improved joint pain in the majority of patients. Despite treatment with ZA, most patients with ON of hips had progressive joint destruction requiring arthroplasty. Patients with ON of the knees appeared to have radiological stabilization. Novel treatment strategies should be considered to prevent this debilitating complication in survivors of childhood cancer., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
24. Renal tubular dysgenesis associated with in utero exposure to Nimuselide.
- Author
-
Ali US, Khubchandani S, Andankar P, Parekhji S, Dubhalish V, and Padhye B
- Subjects
- Female, Humans, Infant, Newborn, Male, Pregnancy, Abnormalities, Drug-Induced etiology, Cyclooxygenase Inhibitors adverse effects, Kidney Tubules abnormalities, Prenatal Exposure Delayed Effects chemically induced, Renal Insufficiency chemically induced, Sulfonamides adverse effects
- Abstract
Maternal ingestion of the selective cyclo-oxygenase-2 (COX-2) inhibitor Nimuselide has been reported to be associated with the development of oligohydramnios and neonatal renal failure in some cases. We report a case of neonatal renal failure associated with maternal ingestion of Nimuselide in the third trimester of pregnancy. The neonate presented with metabolic acidosis and non-oliguric renal failure on the second day of life. The renal histopathology showed evidence of renal tubular dysgenesis. The child continues to have elevated serum creatinine and hypertension at 10 months of age.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.